Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes | Zendy

Andrea Mari | Zendy; William M. Sallas | Zendy; YanLing He | Zendy; C. E. Watson | Zendy; Monica LiguerosSaylan | Zendy; Beth E. Dunning | Zendy; Carolyn F. Deacon | Zendy; Jens J. Holst | Zendy; James E. Foley | Zendy

Open Access

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

Author(s) -

Andrea Mari,

William M. Sallas,

YanLing He,

C. E. Watson,

Monica LiguerosSaylan,

Beth E. Dunning,

Carolyn F. Deacon,

Jens J. Holst,

James E. Foley

Publication year - 2005

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2004-2460

Subject(s) - vildagliptin , medicine , endocrinology , insulin , liter , type 2 diabetes , diabetes mellitus , glucagon like peptide 1 , glucagon , dipeptidyl peptidase , chemistry , dipeptidyl peptidase 4 , enzyme , biochemistry

The dipeptidyl peptidase IV inhibitor, vildagliptin, increases levels of intact glucagon-like peptide-1 (GLP-1) and improves glycemic control in patients with type 2 diabetes. Although GLP-1 is known to stimulate insulin secretion, vildagliptin does not affect plasma insulin levels in diabetic patients, suggesting that more sophisticated measures are necessary to ascertain the influence of vildagliptin on beta-cell function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research